Umoja Biopharma Stock Price, Funding, Valuation, Revenue

Jun 15, 2021 · Funding, Valuation & Revenue. 2 Fundings. Umoja Biopharma has raised $263M over 2 rounds.. Umoja Biopharma's latest funding round was a Series B for $210M on June …

$263
OFF

Umoja Biopharma Stock Price, Funding, Valuation, Revenue

2 weeks from now

Jun 15, 2021 · Funding, Valuation & Revenue. 2 Fundings. Umoja Biopharma has raised $263M over 2 rounds.. Umoja Biopharma's latest funding round was a Series B for $210M on June …

cbinsights.com

$100
OFF

Seattle's Umoja Biopharma Raises $100 Million - Puget Sound …

2 weeks from now

5 hours ago · The company's lead treatment is aimed at cancer and autoimmune disease. Seattle-based Umoja Biopharma has raised a $100 million Series C round. With the funding, …

bizjournals.com

$100
OFF

Umoja Biopharma Announces Oversubscribed $100 Million Series …

2 weeks from now

1 day ago · SEATTLE, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc. (Umoja), the clinical-stage leader of in vivo cell therapies that aim to realize the full reach and promise …

morningstar.com

$175
OFF

Biopharma Industry Eyes 2025 Bounceback, Grapples With …

2 weeks from now

1 day ago · The discrepancies came despite all-time stock price highs hit by obesity drug manufacturers Novo Nordisk and Eli Lilly. ... Morgan Stanley estimates that around $175 …

usnews.com

$25
OFF

Amgen's Earnings, And Other News: The Good, Bad And Ugly Of …

2 weeks from now

Jul 29, 2020 · It is believed that the company plans to price each dose between $25 and $30, taking the price of the two-dose course to $50-$60 range. Moderna bucks the trend by adding …

seekingalpha.com

1%
OFF

Why Keryx Biopharma's Auryxia Could Become The Largest Selling ...

2 weeks from now

Aug 8, 2016 · Valuation of the common stock: Net sales of Auryxia were $10.1 million in the U.S. in 2015 or 1% market share. Net sales in the second quarter of 2016 were $8.3 million in the …

seekingalpha.com

FAQs about Umoja Biopharma Stock Price, Funding, Valuation, Revenue Coupon?

How much is Umoja Biopharma worth?

The current valuation of Umoja Biopharma is 00000. What is Umoja Biopharma’s current revenue? The current revenue for Umoja Biopharma is 000000. How much funding has Umoja Biopharma raised over time? Umoja Biopharma has raised $271M. Who are Umoja Biopharma’s investors? ...

Who is Umoja Biopharma?

Established in 2019, Umoja Biopharma is a pre-clinical stage company with expertise in combining immune physiology and genetic engineering. The company has an integrated cellular immunotherapy platform for the treatment of cancer. ...

Who invested in Umoja Biopharma?

Alexandria Venture Investments, CaaS Capital Management, Cormorant Asset Management, Emerson Collective, and Leerink Partners are 5 of 16 investors who have invested in Umoja Biopharma. Who are Umoja Biopharma’s competitors? ...

How many jobs will Umoja Biopharma create?

The company plans to create 100 jobs, with an average annual salary of $160,000, at the facility within five years of its operation. Umoja Biopharma’s manufacturing facility will be located at 725 Tech Court in the Colorado Technology Centre in Louisville, Colorado. ...

Who are the competitors of Umoja Biopharma?

RootPath, Centrose, T3 Pharmaceuticals, Carisma Therapeutics, and Aro Biotherapeutics are some of the 50 competitors of Umoja Biopharma. Discover how our experts ensure you’re getting the most accurate financial data in the industry. ...

What is Umoja & how does it work?

Umoja, founded in 2019, is developing in-body treatments to boost the effectiveness of immune cell therapies, targeting both cancer and autoimmune diseases. On it website, Umoja lists solid tumors, non-Hodgkin lymphoma, multiple myeloma and autoimmune disease as indications for its treatments. ...